All Type of News
KFDA to relieve blacklisted drugs over harmful talc
The Korea Food and Drug Administration is considering relieving some of asbestos-containing 1,112 medicines which are wholly subject to scrapping.
The drug agency said on July 9 that it will work out measures to re...
Doctors challenge new prescription plan
Doctors have threatened to boycott the current system of separating drug dispensing from medical practice, saying the new prescription plan interferes with their professional rights.
"Should the government go ahead...
Short-sighted push-up sales practice to hit pharmaceutical firms
There are mounting voices in the local pharmaceutical industry that Korean drug makers will no longer be dependent on ‘forced sales’ of OTC products to achieve their sales target.
Market experts pointed out that su...
Dongbang eyes ginkgo business
Dongbang Pharm has recently re-initiated its business of Ginkomin (gingko biloba extract), since its discontinuation for 18 years.
The company said it will make this year a year for second take-off by concentrating...
KFDA mulls donation of talc-tainted medicines with asbestos
The Korea Food and Administration is likely to permit the donation of about 1,000 drugs, which were confirmed to have used talc or talcum powders with asbestos, to foreign countries.
Sources say there is a big poss...
Goldman Sachs to invest 40 billion won to Geoyoung
Geoyoung Group said on July 9 that the Goldman Sachs Group, Inc. decided to invest 40 billion won to Geoyoung
In a recent press interview, Geoyoung co-chairman Lee Hee-goo said that Goldman Sachs’s investment will...
Samsung Electronics to promote biosimilar business
Samsung Electronics Co is poised to enter the global bio-similar market together with local biotech firms backed by the government.
The government announced on July 8 that it would inject 155 billion won ($121 mill...
Yuhan set to export Revanex to Indian market
Yuhan Corporation said on July 8 that it signed a licensing agreement with India based Zydus Cadila over the export of its novel acid pump antagonist Revanex (revaprazan) into Indian market.
Under the agreement, Yu...
Green Cross first NDA approval for anticancer drug from US FDA
Green Cross Corporation said on July 7 it received the first new drug approval (NDA) from US Food and Drug Administation for greenstatin, an investigational anticancer drug that inhibits the formation of new blood ves...
New prescription plan is positive, health ministry says
The new prescription plan, which was implemented on a 10-month trial basis in the National Medical Center last year, were evaluated as “positive”, although there is lack of sufficient verification over the new system....
